Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-08

Study Completion Date

2027-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial tests how well aromatherapy essential oils work to manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting. Current drugs that are given for nausea may cause constipation and fatigue. Therefore, there is interest in exploring complementary therapies, like aromatherapy, that do not carry the same side effects. Using aromatherapy essential oils such as ginger, peppermint, and lavender, may help reduce nausea and anxiety. Some studies have shown significant reductions in nausea and anxiety among cancer patients using these oils, while other studies have had mixed results. Ginger and peppermint oils, in particular, have been associated with helping reduce nausea during chemotherapy, while lavender has shown potential benefits for anxiety. Jojoba oil will be used as a placebo for this research study. Jojoba oil is extracted from the seeds of a jojoba plant, which is a green shrub that is found in the southwestern United States). Jojoba oil is an oil which has no color or smell. Aromatherapy essential oils used through a personal inhalation device during chemotherapy may better manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Aromatherapy for Symptom Management

NCT02163369

Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients

UNKNOWN NA

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

NCT03858855

Gastrointestinal Cancer Neuroendocrine Carcinoma Skin Cancer

COMPLETED NA

Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy

NCT02445378

Acute Leukemia Anorexia Anxiety +5 more

COMPLETED NA

Outpatient Oncology Aromatherapy for Symptom Management

NCT04449315

Anxiety Nausea

UNKNOWN NA

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630

Nausea Vomiting

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the feasibility of utilizing aromatherapy essential oils during outpatient infusions.

II. To assess satisfaction of patients receiving aromatherapy essential oils during outpatient infusions.

SECONDARY OBJECTIVES:

I. To observe whether aromatherapy essential oils (compared to placebo aromatherapy) influence an increase or decrease in nausea in patients undergoing moderate-risk and a high-risk emetogenic chemotherapy regimen.

II. To observe whether aromatherapy essential oils (compared to placebo aromatherapy) influence an increase or decrease in anxiety in patients receiving infusions in the outpatient setting.

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients inhale peppermint essential oil via the personal inhalation device (PID) once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the peppermint essential oil via the PID at least three times a day for 4 days.

ARM II: Patients inhale lavender essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the lavender essential oil via the PID at least three times a day for 4 days.

ARM III: Patients inhale ginger essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the ginger essential oil via the PID at least three times a day for 4 days.

ARM IV: Patients inhale placebo jojoba essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the placebo jojoba essential oil via the PID at least three times a day for 4 days.

After completion of study intervention, patients are followed up at day 25.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (peppermint oil)

Patients inhale peppermint essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the peppermint essential oil via the PID at least three times a day for 4 days.

Group Type EXPERIMENTAL

Aromatherapy and Essential Oils

Intervention Type PROCEDURE

Inhale peppermint oil

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Arm II (lavender oil)

Patients inhale lavender essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the lavender essential oil via the PID at least three times a day for 4 days.

Group Type EXPERIMENTAL

Aromatherapy and Essential Oils

Intervention Type PROCEDURE

Inhale lavender oil

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Arm III (ginger oil)

Patients inhale ginger essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the ginger essential oil via the PID at least three times a day for 4 days.

Group Type EXPERIMENTAL

Aromatherapy and Essential Oils

Intervention Type PROCEDURE

Inhale ginger oil

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Arm IV (placebo jojoba oil)

Patients inhale placebo jojoba essential oil via the PID once every hour starting on day 1 during their anti-cancer/chemotherapy infusions. Patients continue to inhale the placebo jojoba essential oil via the PID at least three times a day for 4 days.

Group Type PLACEBO_COMPARATOR

Aromatherapy and Essential Oils

Intervention Type PROCEDURE

Inhale placebo jojoba oil

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aromatherapy and Essential Oils

Inhale peppermint oil

Intervention Type PROCEDURE

Aromatherapy and Essential Oils

Inhale lavender oil

Intervention Type PROCEDURE

Aromatherapy and Essential Oils

Inhale ginger oil

Intervention Type PROCEDURE

Aromatherapy and Essential Oils

Inhale placebo jojoba oil

Intervention Type PROCEDURE

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aromatherapy Aromatherapy Aromatherapy Aromatherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements
* Ability to read and understand English for patient reported outcomes
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Willingness to comply with all study interventions of essential oil aromatherapy
* Have been on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the National Comprehensive Cancer Network (NCCN) for at least 1 cycle of therapy
* At least 2 remaining infusion appointments on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the NCCN
* Have nausea defined as \> 3/10 with last chemotherapy infusion based on screening symptom questionnaire
* The study is open to all participants regardless of gender, race, or ethnicity

Exclusion Criteria

* Self-reported aversion or sensitivity to lavender oil, peppermint oil, ginger oil, jojoba oil
* Uncontrolled respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD)
* Mental incapacitation (ex. stroke, brain metastasis etc.) that would cause inability to follow directions, in the opinion of the investigators
* Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use)
* Self-reported abnormal smelling abilities (for ex: ongoing sinus infections, long covid, etc.)
* Aromatherapy use in the last 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No